These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 184804)

  • 1. Cardiovascular effects of UK 14,275: evaluation of a new phosphodiesterase inhibitor with inotropic properties in animals and human volunteers [proceedings].
    Follath F; Kersting F; Lewis GR; Dollery CT
    Br J Clin Pharmacol; 1975 Aug; 2(4):372P-373P. PubMed ID: 184804
    [No Abstract]   [Full Text] [Related]  

  • 2. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
    Alvarez R; Banerjee GL; Bruno JJ; Jones GL; Littschwager K; Strosberg AM; Venuti MC
    Mol Pharmacol; 1986 Jun; 29(6):554-60. PubMed ID: 3012320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo myocardial effects of a cyclic AMP phosphodiesterase inhibitor structurally related to natural cardenolides.
    Prigent AF; Nemoz G; Roche M; Pacheco H
    Arch Int Pharmacodyn Ther; 1979 Sep; 241(1):131-52. PubMed ID: 230791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proceedings: Enhancement of ADP-induced platelet aggregation by isometric hand-grip excercise in sclerotic patients and its prevention by EG-626, cAMPPDE inhibitor.
    Sano T; Motimiya T; Yamazaki H; Shinamoto T
    Thromb Diath Haemorrh; 1975 Sep; 34(1):344. PubMed ID: 171796
    [No Abstract]   [Full Text] [Related]  

  • 5. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
    Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
    J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase inhibitors as antiplatelet agents in vascular surgery.
    Kambayashi J; Watase M; Kawasaki T; Shiba E; Sakon M; Mori T; Isaka Y; Kimura K; Kamada T
    Adv Second Messenger Phosphoprotein Res; 1992; 25():383-93. PubMed ID: 1313269
    [No Abstract]   [Full Text] [Related]  

  • 7. Demonstration of functional compartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors.
    Ashida S; Sakuma K
    Adv Second Messenger Phosphoprotein Res; 1992; 25():229-39. PubMed ID: 1313259
    [No Abstract]   [Full Text] [Related]  

  • 8. Multiple molecular forms of phosphodiesterase and the regulation of cardiac muscle contractility.
    Weishaar RE; Kobylarz-Singer DC; Quade MM; Steffen RP; Kaplan HR
    J Cyclic Nucleotide Protein Phosphor Res; 1986-1987; 11(7):513-27. PubMed ID: 2831259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.
    Lorthiois E; Bernardelli P; Vergne F; Oliveira C; Mafroud AK; Proust E; Heuze L; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Wrigglesworth R; Descours A; Soulard P; Berna P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4623-6. PubMed ID: 15324876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cyclic AMP phosphodiesterase activity and myocardial contractility: effects of cilostamide, a novel PDE inhibitor, and methylsiobutylxanthine on rabbit and canine ventricular muscle.
    Endoh M; Satoh K; Yamashita S
    Eur J Pharmacol; 1980 Aug; 66(1):43-52. PubMed ID: 6157546
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclic-AMP-dependent positive chrono- and inotropic responses in the blood-perfused dog atrium.
    Chiba S; Karasawa Y; Furukawa Y
    Adv Second Messenger Phosphoprotein Res; 1992; 25():363-72. PubMed ID: 1372814
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds.
    de Cheffoy de Courcelles D; de Loore K; Freyne E; Janssen PA
    J Pharmacol Exp Ther; 1992 Oct; 263(1):6-14. PubMed ID: 1328613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QSAR study of phosphodiesterase inhibitory activity of imidazo[2,1-b]-quinazolines: active site analysis.
    Prabhakar YS
    Drug Des Deliv; 1989 Dec; 5(2):81-91. PubMed ID: 2577989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular responses to a newly developed phosphodiesterase inhibitor, DN-9693 [7-pyperidinyl-1,2,3,5-tetrahydroimidazo (2,1-b)-quinazolin-2-one.HCl] in dog cross-circulated atrial and ventricular preparations.
    Akahane K; Furukawa Y; Haniuda M; Karasawa Y; Chiba S
    Jpn Heart J; 1989 Nov; 30(6):903-15. PubMed ID: 2561162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DN 9693: a phosphodiesterase inhibitor with a platelet membrane effect.
    Jackson C; Ball J; Peel J; Lawry J; Greaves M; Preston FE
    Thromb Haemost; 1989 Apr; 61(2):266-9. PubMed ID: 2546286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of four methylxanthine compounds and norepinephrine on cardiac phosphorylase activation and cardiac contractility.
    McNeill JH; Brenner MJ; Muschek LD
    Recent Adv Stud Cardiac Struct Metab; 1973; 3():261-73. PubMed ID: 4377599
    [No Abstract]   [Full Text] [Related]  

  • 17. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
    Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
    J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries.
    Birk S; Edvinsson L; Olesen J; Kruuse C
    Eur J Pharmacol; 2004 Apr; 489(1-2):93-100. PubMed ID: 15063160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives.
    Bernardelli P; Lorthiois E; Vergne F; Oliveira C; Mafroud AK; Proust E; Pham N; Ducrot P; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Chevalier E; Descours A; Berlioz-Seux F; Berna P; Li M
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4627-31. PubMed ID: 15324877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inotropic effects of UK 14,275, a phosphodiesterase inhibitor, in man.
    Jackson PG; Jackson G; Kitson D; Jewitt DE
    Br J Clin Pharmacol; 1978 Jan; 5(1):7-11. PubMed ID: 619936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.